ReviewNature reviews. Rheumatology2014
Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.
Review in Nature reviews. Rheumatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus.Frontiers in immunology · 2018Trial
- Integrative Analyses Identify a cGAS-STING Pathway-Driven Signature With Context-Dependent Roles in Systemic Lupus Erythematosus.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Inhibition of polymorphonuclear cells averts cytotoxicity against hypoimmune cells in xenotransplantation.Nature communications · 2025Article
- MDIC3: Matrix decomposition to infer cell-cell communication.Patterns (New York, N.Y.) · 2024Article
- Endoplasmic Reticulum Stress in Systemic Lupus Erythematosus and Lupus Nephritis: Potential Therapeutic Target.Journal of immunology research · 2023Review
- Integrative Analysis of mFrontiers in cell and developmental biology · 2021Article
- Integrated multi-omics approaches to improve classification of chronic kidney disease.Nature reviews. Nephrology · 2020Review
- Lupus community panel proposals for optimising clinical trials: 2018.Lupus science & medicine · 2018Review
- Epigenetic involvement in etiopathogenesis and implications in treatment of systemic lupus erythematous.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Review
- New Perspectives in Rheumatology: May You Live in Interesting Times: Challenges and Opportunities in Lupus Research.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
- Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
- Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.Journal of immunology research · 2017Review
- Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial.Lupus science & medicine · 2017Article
- A Novel Mechanism for Generating the Interferon Signature in Lupus: Opsonization of Dead Cells by Complement and IgM.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Update on Biologic Therapies for Systemic Lupus Erythematosus.Current rheumatology reports · 2016Review
- Inducible T-cell co-stimulator ligand (ICOSL) blockade leads to selective inhibition of anti-KLH IgG responses in subjects with systemic lupus erythematosus.Lupus science & medicine · 2016Article
- Neutrophils Regulate Humoral Autoimmunity by Restricting Interferon-γ Production via the Generation of Reactive Oxygen Species.Cell reports · 2015Article
- Predominant Role of Plasmacytoid Dendritic Cells in Stimulating Systemic Autoimmunity.Frontiers in immunology · 2015Review
- Clinical trials in systemic lupus erythematosus: a status report on ongoing trials.Rheumatology international · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite rapid accumulation of knowledge about complex immune dysregulation in systemic lupus erythematosus (SLE) and major primary lupus syndromes, and a plethora of promising new treatments reaching preclinical and early clinical studies, advanced-phase trials of new biologic agents have repeatedly failed to achieve their clinical end points. It is possible that none of these agents work, but the accuracy of this suggestion is as unclear as the case for efficacy, owing to issues in the design of studies and the opacity of the data that have resulted. Disease heterogeneity and complexity might be a hurdle that is simply too high to overcome by existing methodological approaches, and the way forward to interpretable trial results remains unclear. Nonetheless, well-characterized patterns of immune pathology are shared by substantial subsets of patients, and selective targeting of one or more relevant immune system molecules seems to offer the promise of safer and more effective treatments. Evolution dictates a more personalized approach to therapy and trial design, but this option seems challenging in the current economic, regulatory and scientific environment. This Review addresses these concerns by considering the progress of some of the investigational treatments targeting key physiological abnormalities in lupus.
Indexed as
Identifiers
24100460What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.